Ocugen, Inc. — Director's Dealing 2017

Jun 14, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HISTOGENICS CORP (HSGX)
CIK: 0001372299
Period of Report: 2017-06-13

Reporting Person: Kong Garheng (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-06-13	Stock Option (Right to Buy)	$1.70	A	25000	Acquired	2027-06-12	Common Stock (25000)	Direct

Footnotes

F1: This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 13, 2017.